Article

Dietary magnesium, lung function, wheezing, and airway hyperreactivity in random adult population sample

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States
The Lancet (Impact Factor: 45.22). 09/1994; 344(8919):357-62. DOI: 10.1016/S0140-6736(94)91399-4
Source: PubMed

ABSTRACT Magnesium is involved in a wide range of biological activities, including some that may protect against the development of asthma and chronic airflow obstruction. We tested the hypothesis that high dietary magnesium intake is associated with better lung function, and a reduced risk of airway hyper-reactivity and wheezing in a random sample of adults. In 2633 adults aged 18-70 sampled from the electoral register of an administrative area of Nottingham, UK, we measured dietary magnesium intake by semiquantitative food-frequency questionnaire, lung function as the 1-sec forced expiratory volume (FEV1), and atopy as the mean skin-prick test response to three common environmental allergens. We measured airway reactivity to methacholine in 2415 individuals, defining hyper-reactivity as a 20% fall in FEV1 after a cumulative dose of 12.25 mumol or less. Mean (SD) daily intake of magnesium was 380 (114) mg/day. After adjusting for age, sex, and height, and for the effects of atopy and smoking, a 100 mg/day higher magnesium intake was associated with a 27.7 (95% CI, 11.9-43.5) mL higher FEV1, and a reduction in the relative odds of hyper-reactivity by a ratio of 0.82 (0.72-0.93). The same incremental difference in magnesium intake was also associated with a reduction in the odds of self-reported wheeze within the past 12 months, adjusted for age, sex, smoking, atopy, and kilojoule intake, by a ratio of 0.85 (0.76-0.95). Dietary magnesium intake is independently related to lung function and the occurrence of airway hyper-reactivity and self-reported wheezing in the general population. Low magnesium intake may therefore be involved in the aetiology of asthma and chronic obstructive airways disease.

1 Follower
 · 
300 Views
  • Source
    • "A potential role for Mg supplementation in regard to physical performance may be pronounced in these patients. Dietary Mg intake has been shown to be related to lung function, airway reactivity, and respiratory symptoms (8,9). Some studies have suggested that patients with chronic obstructive pulmonary disease (COPD) may exhibit decreased body levels of Mg (10-12). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The potential influence of magnesium on exercise performance is a subject of increasing interest. Magnesium has been shown to have bronchodilatatory properties in asthma and chronic obstructive pulmonary disease patients. The aim of this study was to investigate the effects of acute magnesium IV loading on the aerobic exercise performance of stable chronic obstructive pulmonary disease patients. Twenty male chronic obstructive pulmonary disease patients (66.2 + 8.3 years old, FEV1: 49.3+19.8%) received an IV infusion of 2 g of either magnesium sulfate or saline on two randomly assigned occasions approximately two days apart. Spirometry was performed both before and 45 minutes after the infusions. A symptom-limited incremental maximal cardiopulmonary test was performed on a cycle ergometer at approximately 100 minutes after the end of the infusion. Magnesium infusion was associated with significant reductions in the functional residual capacity (-0.41 l) and residual volume (-0.47 l), the mean arterial blood pressure (-5.6 mmHg) and the cardiac double product (734.8 mmHg.bpm) at rest. Magnesium treatment led to significant increases in the maximal load reached (+8 w) and the respiratory exchange ratio (0.06) at peak exercise. The subgroup of patients who showed increases in the work load equal to or greater than 5 w also exhibited significantly greater improvements in inspiratory capacity (0.29 l). The acute IV loading of magnesium promotes a reduction in static lung hyperinflation and improves the exercise performance in stable chronic obstructive pulmonary disease patients. Improvements in respiratory mechanics appear to be responsible for the latter finding.
    Clinics (São Paulo, Brazil) 06/2012; 67(6):615-22. DOI:10.6061/clinics/2012(06)12 · 1.42 Impact Factor
  • Source
    • "As pre-existing magnesium deficit could be associated with risk of asthma exacerbation [32-35], one might think that serum magnesium level could be measured for adequate supplementation or prediction of treatment response. However, it is predominantly an intracellular ion, and its serum level does not reflect intracellular concentrations or total body stores. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Magnesium sulfate (MgSO(4)) has been considered as an adjunct therapy for severe and life-threatening asthma exacerbation. The literature search was performed using MEDLINE, EMBASE, Cochrane Library and Google Scholar to summarize the current state of knowledge regarding magnesium therapy in acute exacerbation of adult asthma. A total of 16 trials and 4 meta-analyses were identified. As results, intravenous MgSO(4) was beneficial in severe exacerbation, but evidence for nebulized magnesium was insufficient. However, larger trials are required to draw confirmative conclusions on the efficacy. Regarding the safety concern, the risk of major toxicity appears to be very low at usual doses described in the literature. Additionally, results from 4 surveys were examined on the gaps between knowledge and practice, and on the barrier to the use of MgSO(4) at emergency departments. This literature review summarized the up-to-date evidence on the issues regarding the use of MgSO(4) for acute asthma. We expect more studies to be conducted for evidence making in the Asian-Pacific regions.
    01/2012; 2(1):76-85. DOI:10.5415/apallergy.2012.2.1.76
  • Source
    • "Gedling is an area of 46 square miles with an estimated population of 87,000 in 1991 which covers the north east suburbs of Nottingham and surrounding rural villages. Full details of the study have been described elsewhere[13]. Briefly, a representative sample of adults was drawn from the local electoral register and those of eligible age and residing in the study area were invited to take part in the study (figure 1). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Epidemiological research into the role of traffic pollution on chronic respiratory and allergic disease has focused primarily on children. Studies in adults, in particular those based on objective outcomes such as bronchial hyperresponsiveness, skin sensitisation, and lung function, are limited. We have used an existing cohort of 2644 adults aged 18-70 living in Nottingham, UK, for whom baseline health and demographic data were collected in 1991 and computed two markers of exposure to traffic: distance between the home and nearest main road and modelled outdoor nitrogen dioxide (NO2) concentration at the home location. Using multiple regression techniques, we analysed cross-sectional associations with bronchial hyperresponsiveness, FEV1, spirometry-defined COPD, skin test positivity, total IgE and questionnaire-reported wheeze, asthma, eczema and hayfever in 2599 subjects, and longitudinal associations with decline in FEV1 in 1329 subjects followed-up nine years later in 2000. There were no significant cross-sectional associations between home proximity to the roadside or NO2 level on any of the outcomes studied (adjusted OR of bronchial hyperresponsiveness in relation to living < or =150 m vs >150 m from a road = 0.92, 95% CI 0.68 to 1.24). Furthermore, neither exposure was associated with a significantly greater decline in FEV1 over time (adjusted mean difference in DeltaFEV1 for living < or =150 m vs >150 m of a road = 10.03 ml, 95% CI, -33.98 to 54.04). This study found no evidence to suggest that living in close proximity to traffic is a major determinant of asthma, allergic disease or COPD in adults.
    BMC Pulmonary Medicine 08/2009; 9(1):42. DOI:10.1186/1471-2466-9-42 · 2.49 Impact Factor
Show more